Sykehuset Oestfold HF Kalnes
- Address
- lock Available on a paid plan
Cardiovascular Diseases
At Sykehuset Oestfold HF Kalnes, the Department of Cardiology is involved in studies focused on acute myocardial infarction, atrial fibrillation, and prevention of ischemic stroke. This research is centered on testing new treatment approaches and improving protection against serious heart and blood-clotting complications.
- Preventing recurrent heart attacks in people at risk of acute myocardial infarction
- Reducing stroke and systemic embolism in atrial fibrillation
- Lowering the risk of ischemic stroke after recent stroke or high-risk transient ischemic attack
The site’s cardiovascular research aims to strengthen treatment options and improve outcomes for patients with high-risk cardiovascular disease.
Neoplasms
Clinical trials at this hospital also address several forms of cancer, including clear cell renal cancer, melanoma, and Diffuse Large B-Cell Lymphoma. These studies are designed to evaluate newer cancer therapies and compare them with established treatment strategies.
- Testing combination treatments for advanced clear cell renal cell carcinoma
- Studying ways to prevent recurrence after resected melanoma
- Assessing treatment effectiveness in Diffuse Large B-Cell Lymphoma
This research reflects a strong interest in improving survival and long-term disease control across different oncology settings.
Nutritional and Metabolic Diseases
Research in this area includes non-alcoholic steatohepatitis, a liver condition closely linked to metabolic risk factors such as obesity and diabetes. The trial activity is aimed at evaluating safety, tolerability, and biological effects of a potential new therapy for patients with liver fibrosis.
- Evaluating a new treatment approach for non-cirrhotic NASH with fibrosis
- Exploring disease mechanisms related to metabolism and liver injury
- Supporting development of therapies for progressive fatty liver disease
These studies highlight the site’s interest in conditions where metabolic dysfunction contributes to long-term organ damage.
Virus Diseases
The site is participating in research on emerging and widespread viral infections, including mpox virus disease and COVID-19. The trials focus on understanding clinical outcomes and assessing whether antiviral or other treatment strategies can improve recovery in hospitalized patients.
- Observing outcomes in patients with mpox virus disease
- Evaluating treatment approaches for hospitalized COVID-19 patients
- Studying care strategies for coronavirus infection in moderate and severe illness
These infectious disease studies support better care for patients affected by both newly emerging and globally significant viral illnesses.
Hemic and Lymphatic Diseases
Trial activity in this therapeutic area includes Diffuse Large B-Cell Lymphoma, with research aimed at comparing treatment options and improving outcomes for patients with blood cancers. The studies are intended to help define more effective and better-tolerated therapy choices.
- Comparing treatment strategies for lymphoma
- Assessing effectiveness in hematologic malignancy
- Supporting better disease control in blood cancer
This work adds to the site’s broader focus on oncology and treatment optimization.
Pathological Conditions, Signs and Symptoms
Some studies at Sykehuset Oestfold HF Kalnes address acute clinical conditions and symptom-driven care, including patients hospitalized with moderate COVID-19 and those with suspected acute myocardial infarction. The purpose is to test whether new treatments can improve short-term outcomes in urgent care settings.
- Improving outcomes in hospitalized patients with moderate COVID-19
- Evaluating treatment response in suspected acute myocardial infarction
- Supporting faster and more effective management of serious clinical symptoms
These trials reflect a practical focus on conditions where rapid treatment decisions can make a major difference.
Metabolism
In addition to liver disease research, the site contributes to studies connected with metabolism and cardiometabolic risk. This includes work that links metabolic health with cardiovascular and liver outcomes, helping researchers better understand how these conditions interact.
- Exploring the role of metabolic dysfunction in chronic disease
- Connecting liver, heart, and vascular health in clinical research
- Supporting development of treatments for metabolism-related disorders
These investigations broaden the site’s clinical research portfolio beyond single diseases and into shared disease pathways.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 22 therapeutic areas and 15 of 134 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 128 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 26 by active trials.
- 1Oslo University Hospital HF8active
lock +25 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Oslo University Hospital HF13trials
lock +11 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 112 other sites in Norway
Therapeutic Area Benchmark — Norway
Select a therapeutic area to compare against other sites in Norway.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Norway
Market Share
Country: Norway
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Sykehuset Oestfold HF Kalnes
lock Showing 1 of 63 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A multi-center, open-label, single-arm study to evaluate the efficacy and safety of oral rilzabrutinib in adults with immune thrombocytopenia (ITP) who failed first-line treatment | Sanofi-Aventis Recherche & Developpement | Phase III | Recruiting | Dec 2025 | — |
IMP list
lock Showing 1 of 134 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Sodium Chloride | 5 | Unknown | 2020-10-30 | 2025-06-06 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.